Member Info for liquid1

Yesterday ‘s date Probably out today, and another RNS tomorrow. Maybe delayed big sells after 4:30pm to show Woodford is out

Woodford RNS appears to come after 4:00pm So today or tomorrow 26 Jun 2019 4:41 pm RNS Report Factsheet e-Therapeutics plc (ETX) Holding(s) in Company 06 Jun 2019 3:58 pm RNS Report Factsheet e-Therapeutics plc (ETX) Holding(s) in Company

Medical World

@MedicalWorld110

Cancer Research, UK top funded charity, to fund only 2 cannabinoid clinical trials, 1 for synthetic cannabinoid Dexanabinol by e-Therapeutics & another Sativex, cannabis plant extract by GW Pharma.

5
1:35 PM - Jun 26, 2019

https://twitter.com/MedicalWorld110/media

As per RNS 5th March: 26p

YES RNS not some bloke on BB?????

10 x current value

https://www.investegate.co.uk/edison-investment-research-lim--etx-/eqs/edison-issues-update-on-e-therapeutics--etx-/20190305155101ETGHT/

Doubters

26p target!!!!!

Check out RNS 5th March 2019

https://www.investegate.co.uk/edison-investment-research-lim--etx-/eqs/edison-issues-update-on-e-therapeutics--etx-/20190305155101ETGHT/

KeywordCompanyEPIC/TIDMSEDOL/ISINNews

Search
Price
Announcements
Fundamentals
News
Article
RSS
Edison Investment Research Lim (ETX)
Add to Alerts list
Print Mail a friend Annual reports
Tuesday 05 March, 2019
Edison Investment Research Lim
Edison issues update on e-Therapeutics (ETX)
Edison Investment Research Limited
Edison issues update on e-Therapeutics (ETX)

05-March-2019 / 15:51 GMT/BST

London, UK, 5 March 2019

Edison issues update on e-Therapeutics (ETX)

e-Therapeutics' (ETX) FY19 results demonstrated continued financial prudence and its focus on partnering, out-licensing and non-dilutive financing. The FY19 operating loss was £5.1m, which is the same as our estimate. The cash outflow was £3.7m, resulting in a cash balance of £5.9m at the end of FY19. Both R&D and administrative expenses had been reduced from FY18 and the recently announced Novo collaboration generated £0.04m in FY19.

We have updated our valuation to £69.4m or 26p/share, from £63.5m (24p/share), due to the impact of a stronger dollar on the dollar-based comparative transactions. All underlying assumptions remain unchanged. ETX expects more collaborations, and more visible transactions than the Novo collaboration and we would expect these to be incorporated into ETX's valuation when they occur.

https://www.investegate.co.uk/edison-investment-research-lim--etx-/eqs/edison-issues-update-on-e-therapeutics--etx-/20190305155101ETGHT/

Securities in issue Number of AIM securities in issue: 268,689,878 ordinary shares of 0.1p Percentage of AIM securities not in public hands: 68.77% Listing: AIM Index: FTSE AIM All Share Sector: Pharmaceutical & Biotechnology Symbol: ETX There are no restrictions on the transfer of the Company’s shares. Last updated: 10 June 2019 https://www.etherapeutics.co.uk/investors/shareholder-information/

Reason for the rise: RE: Medical World Tweet https://twitter.com/MedicalWorld110 Medical World ? @MedicalWorld110 2h2 hours ago More Cancer Research, UK top funded charity, to fund only 2 cannabinoid clinical trials, 1 for synthetic cannabinoid Dexanabinol by e-Therapeutics & another Sativex, cannabis plant extract by GW Pharma.

Is that Woodford out!!!

The global medical cannabis market, which is projected to grow at a CAGR of 22.9% during 2019-2024 to reach a value of $44.4 billion by 2024, according to a report by imarc.

The report states that cannabis is a preferred treatment option as it is safer and has fewer side effects. Cancer is the biggest area of application for medical cannabis while others include arthritis, migraine, and epilepsy. North America is the largest market for medical cannabis while other key regions include Europe, Asia Pacific, Latin America, and the Middle East and Africa.

https://news.alphastreet.com/deep-focus-everything-you-need-to-know-about-gw-pharmaceuticals/

https://twitter.com/MedicalWorld110

Medical World
?

@MedicalWorld110
2h2 hours ago
More
Cancer Research, UK top funded charity, to fund only 2 cannabinoid clinical trials, 1 for synthetic cannabinoid Dexanabinol by e-Therapeutics & another Sativex, cannabis plant extract by GW Pharma.

Medical World
?


Interesting Coldspy!

@MedicalWorld110
Follow Follow @MedicalWorld110
More
Cancer Research, UK top funded charity, to fund only 2 cannabinoid clinical trials, 1 for synthetic cannabinoid Dexanabinol by e-Therapeutics & another Sativex, cannabis plant extract by GW Pharma.

MM tricks

IQ-AI Limited (LON:IQAI) is the company formerly known as Flying Brands. The name change reflected its aspiration of becoming a leader in the field of medical imaging diagnostics. It currently comprises two businesses - Stone Checker Software and Imaging Biometrics (IB).

StoneChecker

This is predictive diagnostic software product that helps urologists determine whether a kidney stone will disintegrate under a vibration process called lithotripsy. This capability becomes important in determining whether to subject patients to multiple rounds of lithotripsy or send them straight to surgery. Its products are now sold in the USA, UK, The Netherlands, Switzerland, Germany, Greece and South Korea.

Imaging Biometrics

IB provides advanced imaging software used by cancer hospitals and universities in the US such as the Mayo Clinic and Stanford University Medical Centre. One application is commercialising aids in the detection and staging of chronic liver disease, while another “leverages deep learning algorithms” for breast cancer screening.

https://www.proactiveinvestors.co.uk/companies/news/220929/iq-ai-becoming-a-leader-in-the-field-of-medical-imaging-diagnostics-220929.html

StoneChecker is an innovative medical software designed to aid clinical decision making by providing information about a patient’s kidney stone. The StoneChecker software tool is designed to be a streamlined semi-automated stone assessment tool that provides physicians with all the useful clinical metrics instantly using the patient’s non-contrast CT scans. Stone Checker Software Ltd has an exclusive worldwide licence to apply the TexRAD® algorithm (provided by TexRAD Ltd., www.TexRAD.com, part of Feedback Plc) to examine heterogeneity and ‘texture’ not visible to the naked eye. Tested and validated at the University of Oxford, StoneChecker software has been available for research use since 2017 and is now available for commercial use outside the U.S. https://www.imagingbiometrics.com/what-we-offer/product-services/ib-stonechecker/

3 weeks since he stated FDA Approval coming. We were in the queue awaiting to come out the other end! Hope we are now very close to rubber stamp. Placing fears out of the way! The only way is up to RENX type market cap

Products are tomorrow’s technology! NO debt! 6m in the bank

They want 4.5p for any amount! Tree shake???

Can’t get any quotes on the drop!

Onwards towards 15p please